PTO/SB/26 (01-08)
Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of	
TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 17359CON2CIP1CIP1 (BOT)
In re Application of: Stephen Donovan	
Application No.: 10/752,871	
Filed: 01-06-2004	
For: Intravitreal Botulinum Toxin Implant	
The owner", ALLERGAN, INC. scopt as provided below, the terminal part of the statutory term of any patent granted on the instant application hierarchy disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend become the expiration date of the full statutory term prior patent No. 8,585,902. and 173, and as the term of said prior patent part patent part patent part patent pa	
and the search of the explanation case or the institution of the search	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willight false statements here like so made are punishable by fine or imprisonment, or both, under Section 1001 of 17tle 16 of the United States Code and that such willful false statements may logorardize the validity of the application or any patent issued thereon.	
The undersigned is an attorney or agent of record. Reg. No. 33,433	
/Stephen Donovan/	7-30-08
Signature	Date
Stephen Donovan	
Typed or printed name	
	(714) 246-4026 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement_under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to processe) an application is estimated to take 12 minutes to complete to processe in a special processe in a special